A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

Published:2022-06-03 Issue:7 Volume:31 Page:747-757
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Cho Byoung Chul¹,Goldberg Sarah B²,Kim Dong-Wan³,Socinski Mark A⁴,Burns Timothy F⁵,Lwin Zarnie⁶,Pathan Nuzhat⁷,Ma Wei Dong⁸,Masters Joanna C⁷,Cossons Nandini⁹,Wilner Keith⁷,Nishio Makoto¹⁰,Husain Hatim¹¹

Affiliation:

1. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

2. Department of Medicine, Yale School of Medicine, New Haven, CT, USA

3. Cancer Research Institute, Seoul National University College of Medicine and Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

4. Thoracic Oncology, Advent Health Cancer Institute, Orlando, FL, USA

5. Department of Medicine, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA

6. Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia

7. Translational Oncology, Pfizer Inc, San Diego, CA, USA

8. Biostatistics, Pfizer Inc, New York, USA

9. Lead Study Clinician, Pfizer Inc, UK

10. Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

11. Department of Medicine, UCSD Moores Cancer Center, La Jolla, CA, USA

Funder

Pfizer

Publisher

Informa UK Limited